lusutrombopag and Hepatitis-C

lusutrombopag has been researched along with Hepatitis-C* in 1 studies

Other Studies

1 other study(ies) available for lusutrombopag and Hepatitis-C

Article	Year
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient. Clinical journal of gastroenterology, 2017, Volume: 10, Issue:3 A 56-year-old Japanese man with liver cirrhosis (LC) due to hepatitis C virus was admitted to our hospital for radiofrequency ablation of residual tumor following lusutrombopag administration. Laboratory tests revealed thrombocytopenia and leukopenia. The patient's LC was managed, and he was classified as Child-Pugh A. After admission, lusutrombopag was administered for 7 days. The platelet count increased to over 50,000/mm Topics: Carcinoma, Hepatocellular; Cinnamates; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Thiazoles; Thrombocytopenia	2017

Article

Year

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.

Clinical journal of gastroenterology, 2017, Volume: 10, Issue:3

A 56-year-old Japanese man with liver cirrhosis (LC) due to hepatitis C virus was admitted to our hospital for radiofrequency ablation of residual tumor following lusutrombopag administration. Laboratory tests revealed thrombocytopenia and leukopenia. The patient's LC was managed, and he was classified as Child-Pugh A. After admission, lusutrombopag was administered for 7 days. The platelet count increased to over 50,000/mm

Topics: Carcinoma, Hepatocellular; Cinnamates; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Thiazoles; Thrombocytopenia

2017